- Home
- LILAK vs PTGX Comparison
LILAK vs PTGX Comparison
Compare LILAK & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILAK
- PTGX
- Stock Information
- Founded
- LILAK 2017
- PTGX 2006
- Country
- LILAK Bermuda
- PTGX United States
- Employees
- LILAK N/A
- PTGX N/A
- Industry
- LILAK Cable & Other Pay Television Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- LILAK Telecommunications
- PTGX Health Care
- Exchange
- LILAK Nasdaq
- PTGX Nasdaq
- Market Cap
- LILAK 1.1B
- PTGX 3.3B
- IPO Year
- LILAK N/A
- PTGX 2016
- Fundamental
- Price
- LILAK $6.45
- PTGX $55.23
- Analyst Decision
- LILAK Buy
- PTGX Strong Buy
- Analyst Count
- LILAK 3
- PTGX 9
- Target Price
- LILAK $10.27
- PTGX $67.11
- AVG Volume (30 Days)
- LILAK 1.3M
- PTGX 925.2K
- Earning Date
- LILAK 08-05-2025
- PTGX 08-05-2025
- Dividend Yield
- LILAK N/A
- PTGX N/A
- EPS Growth
- LILAK N/A
- PTGX N/A
- EPS
- LILAK N/A
- PTGX 0.86
- Revenue
- LILAK $4,441,000,000.00
- PTGX $207,801,000.00
- Revenue This Year
- LILAK $2.45
- PTGX N/A
- Revenue Next Year
- LILAK $3.11
- PTGX $53.09
- P/E Ratio
- LILAK N/A
- PTGX $63.67
- Revenue Growth
- LILAK N/A
- PTGX N/A
- 52 Week Low
- LILAK $4.23
- PTGX $32.50
- 52 Week High
- LILAK $10.93
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- LILAK 63.80
- PTGX 60.92
- Support Level
- LILAK $6.07
- PTGX $49.38
- Resistance Level
- LILAK $6.65
- PTGX $51.51
- Average True Range (ATR)
- LILAK 0.31
- PTGX 2.09
- MACD
- LILAK 0.00
- PTGX -0.14
- Stochastic Oscillator
- LILAK 77.01
- PTGX 74.47
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.